Hege Kilander H.
- Country
- Norway
- Department
- Rheumatology
Research Overview
- Phase 4 Randomized Trial of Maintenance vs Tapered TNF‑α Inhibitor (adalimumab, etanercept, golimumab) Monotherapy in Juvenile Idiopathic Arthritis with Inactive Disease
- Evaluation of Methotrexate and Tumor Necrosis Factor Inhibitor Withdrawal Strategies in Juvenile Idiopathic Arthritis Remission: A Randomized Multicenter Trial
Data & Insights
Has run more than one trial at 2 of 8 partner sites.
Specializations
Pediatric Rheumatology
The investigator specializes in treating juvenile idiopathic arthritis (JIA), focusing on innovative therapeutic approaches for children and adolescents with rheumatic conditions.
- Chronic inflammatory disorders in children
- Autoimmune disease management
- Pediatric joint conditions
Particular expertise in assessing disease activity and developing treatment strategies for sustained remission in pediatric arthritis.
Treatment Optimization
Expert in evaluating and optimizing combination therapies involving methotrexate and tumor necrosis factor inhibitors (TNFi) for pediatric rheumatic conditions.
- Therapeutic drug monitoring
- Treatment withdrawal strategies
- Disease activity assessment
Focuses on developing personalized treatment approaches to maintain disease remission while minimizing medication exposure.
Clinical Assessment
Specializes in evaluating inactive disease states and monitoring disease progression in pediatric rheumatic conditions.
- Long-term disease monitoring
- Flare risk assessment
- Clinical outcome measures
Expertise in implementing standardized assessment criteria for determining disease activity in pediatric patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.